USD 0.477
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ELTP | -1.4 | -6.5 | -14.5 | -11.7 | 147.8 | 150.3 | 1107.6 | 377 | 116.8 | -96.4 |
| S&P 500 | -1.8 | -1.5 | 0.3 | 3.1 | 9.7 | 21.6 | 38.5 | 84.7 | 195.2 | 33820.4 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ELTP |
| name | Elite Pharmaceuticals, Inc. |
| price | 0.477 |
| changes percentage | -1.4463 |
| change | -0.007 |
| day low | 0.4752 |
| day high | 0.485 |
| year high | 0.75 |
| year low | 0.12 |
| market cap | 509564790 |
| price avg 50 | 0.5534 |
| price avg 200 | 0.33155 |
| exchange | PNK |
| volume | 471122 |
| avg volume | 1768720 |
| open | 0.48 |
| previous close | 0.484 |
| eps | -0.01 |
| pe | -47.7 |
| earnings announcement | 2025-02-12T21:00:00.000+0000 |
| shares outstanding | 1068270000 |
| timestamp | 2025-01-27 16:57:12 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001053369 | |||
| revenue | 56625128 | 34155114000 | -99.83 |
| gross profit | 26357103 | 16594021000 | -99.84 |
| gross profit ratio | 0.47 | 0.49 | -4.19 |
| research and development expenses | 6883351 | 6200163000 | -99.89 |
| operating expenses | 15568334 | 12918019000 | -99.88 |
| interest income | 20918 | 7453000 | -99.72 |
| interest expense | 588622 | 1112707 | -47.10 |
| ebitda | 2582725 | 6429094 | -59.83 |
| ebitdaratio | 0.05 | 0.1 | -52.63 |
| operating income | 10788769 | 2025111000 | -99.47 |
| operating income ratio | 0.19 | 0.06 | 221.34 |
| net income | 20108631 | 4409902000 | -99.54 |
| net income ratio | 0.36 | 0.13 | 175.04 |
| eps | 0.02 | 4.35 | -99.54 |
Revenue Growth: revenue increased to 57 million in 2024 from 34,155 million in 2023 representing a change of -99.83%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 7 million in 2024 from 6,200 million in 2023 representing a change of -99.89%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Gross Profit: Gross Profit decreased to 26 million in 2024 from 16,594 million in 2023 representing a change of -99.84%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 16 million in 2024 from 12,918 million in 2023 representing a change of -99.88%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 3 million in 2024 from 6 million in 2023 representing a change of -59.83%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to 11 million in 2024 from 2,025 million in 2023 representing a change of -99.47%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to 20 million in 2024 from 4,410 million in 2023 representing a change of -99.54%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 0.02 in 2024 from 0.02 in 2023 representing a change of -99.54%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2025Q2 | 2025Q1 | Q/Q change % | |
|---|---|---|---|
| 0001053369 | |||
| revenue | 18880345 | 18803063 | 0.41 |
| gross profit | 8197428 | 8474778 | -3.27 |
| gross profit ratio | 0.43 | 0.45 | -3.67 |
| research and development expenses | 1966094 | 2163527 | -9.13 |
| operating expenses | 4712485 | 4185010 | 12.60 |
| interest income | 5902 | 5390 | 9.50 |
| interest expense | 255136 | 250781 | 1.74 |
| ebitda | -8710424 | 1657273 | -625.59 |
| ebitdaratio | -0.46 | 0.09 | -623.44 |
| operating income | 3484943 | 3864056 | -9.81 |
| operating income ratio | 0.18 | 0.21 | -10.18 |
| net income | -11036229 | 615773 | -1892.26 |
| net income ratio | -0.58 | 0.03 | -1884.92 |
| eps | -0.01 | 0.0 | -1816.67 |
Revenue Growth: revenue increased to 19 million in 2025Q2 from 19 million in 2025Q1 representing a change of 0.41%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit decreased to 8 million in 2025Q2 from 8 million in 2025Q1 representing a change of -3.27%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 2 million in 2025Q2 from 2 million in 2025Q1 representing a change of -9.13%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 5 million in 2025Q2 from 4 million in 2025Q1 representing a change of 12.6%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -9 million in 2025Q2 from 2 million in 2025Q1 representing a change of -625.59%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to 3 million in 2025Q2 from 4 million in 2025Q1 representing a change of -9.81%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -11 million in 2025Q2 from 1 million in 2025Q1 representing a change of -1892.26%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.01 in 2025Q2 from -0.01 in 2025Q1 representing a change of -1816.67%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001053369 | |||
| total assets | 83653536 | 40896018 | 104.55 |
| total liabilities | 26070718 | 11935758 | 118.43 |
| total equity | 57582818 | 28960260 | 98.83 |
| cash and cash equivalents | 7106262 | 7832247 | -9.27 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 21018 | -100.00 |
| total current assets | 40014189 | 21510297 | 86.02 |
| total non current assets | 43639347 | 19385721 | 125.11 |
| total current liabilities | 13049764 | 7833637 | 66.59 |
| total non current liabilities | 13020954 | 4102121 | 217.42 |
| common stock | 1068377 | 1014019 | 5.36 |
| retained earnings | -116389267 | -136497898 | 14.73 |
| total debt | 11737768 | 3887288 | 201.95 |
Total Assets: Total Assets increased to 84 million in 2024 from 41 million in 2023 representing a change of 104.55%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 58 million in 2024 from 29 million in 2023 representing a change of 98.83%. This indicates an increase in shareholders' equity.
Total Current Assets: Total Current Assets increased to 40 million in 2024 from 22 million in 2023 representing a change of 86.02%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 1 in 2024 from 1 in 2023 representing a change of 5.36%. This indicates an increase in ownership interest.
Retained Earnings: Retained Earnings increased to -116 million in 2024 from -136 million in 2023 representing a change of 14.73%. This indicates an accumulated profits.
Total Liabilities: Total Liabilities increased to 26 million in 2024 from 12 million in 2023 representing a change of 118.43%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 7 million in 2024 from 8 million in 2023 representing a change of -9.27%. This indicates a decrease in available liquid assets.
Total Current Liabilities: Total Current Liabilities increased to 13 million in 2024 from 8 million in 2023 representing a change of 66.59%. This indicates a higher short-term debt burden.
Total Debt: Total Debt increased to 12 million in 2024 from 4 million in 2023 representing a change of 201.95%. This indicates an increase in overall debt burden.
| 2025Q2 | 2025Q1 | Q/Q change % | |
|---|---|---|---|
| 0001053369 | |||
| total assets | 88197996 | 87846005 | 0.40 |
| total liabilities | 40930976 | 29595085 | 38.30 |
| total equity | 47267020 | 58250920 | -18.86 |
| cash and cash equivalents | 9554963 | 8407152 | 13.65 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 45293849 | 43160540 | 4.94 |
| total non current assets | 42904147 | 44685465 | -3.99 |
| total current liabilities | 12853720 | 14014635 | -8.28 |
| total non current liabilities | 28077256 | 15580450 | 80.21 |
| common stock | 1068377 | 1068377 | 0.00 |
| retained earnings | -126809723 | -115773494 | -9.53 |
| total debt | 11396354 | 11663482 | -2.29 |
Total Assets: Total Assets increased to 88 million in 2025Q2 from 88 million in 2025Q1 representing a change of 0.4%. Suggesting a growth in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 10 million in 2025Q2 from 8 million in 2025Q1 representing a change of 13.65%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 45 million in 2025Q2 from 43 million in 2025Q1 representing a change of 4.94%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 13 million in 2025Q2 from 14 million in 2025Q1 representing a change of -8.28%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 11 million in 2025Q2 from 12 million in 2025Q1 representing a change of -2.29%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 41 million in 2025Q2 from 30 million in 2025Q1 representing a change of 38.3%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 47 million in 2025Q2 from 58 million in 2025Q1 representing a change of -18.86%. This indicates a decrease in shareholders' equity.
Retained Earnings: Retained Earnings decreased to -127 million in 2025Q2 from -116 million in 2025Q1 representing a change of -9.53%. This indicates an accumulated losses.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001053369 | |||
| net change in cash | -705587 | -695715 | -1.42 |
| operating cash flow | -3281558 | 3338704 | -198.29 |
| free cash flow | -4091211 | -2397914 | -70.62 |
| capital expenditure | -809653 | -5736618 | 85.89 |
| depreciation and amortization | 1471584 | 1344683 | 9.44 |
| deferred income tax | -19989074 | 1509616000 | -101.32 |
| stock based compensation | 8513927 | 579325 | 1369.63 |
| accounts payables | 7780962 | 1336566 | 482.16 |
| inventory | -3379748 | -2809546 | -20.30 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -809653 | -5736618 | 85.89 |
| net cash used for investing activites | -809653 | -5736618 | 85.89 |
| debt repayment | 3339181 | 1702199 | 96.17 |
| common stock issued | 159921000 | 39325000 | 306.66 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 3385624 | 1702199 | 98.90 |
| cash at end of period | 7539094 | 8244681 | -8.56 |
| accounts receivables | -16595028 | -36636 | -45197.05 |
| cash at beginning of period | 8244681 | 8940396 | -7.78 |
Net Change in Cash: Net Change in Cash decreased to -1 million in 2024 from -1 million in 2023 representing a change of -1.42%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -3 million in 2024 from 3 million in 2023 representing a change of -198.29%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -4 million in 2024 from -2 million in 2023 representing a change of -70.62%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -1 million in 2024 from -6 million in 2023 representing a change of 85.89%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 9 million in 2024 from 1 million in 2023 representing a change of 1369.63%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 8 million in 2024 from 1 million in 2023 representing a change of 482.16%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -17 million in 2024 from 0 million in 2023 representing a change of -45197.05%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
| 2025Q2 | 2025Q1 | Q/Q change % | |
|---|---|---|---|
| 0001053369 | |||
| operating cash flow | 1456844 | 3144463 | -53.67 |
| free cash flow | 1364399 | 1465936 | -6.93 |
| capital expenditure | -92445 | -1678527 | 94.49 |
| depreciation and amortization | 553471 | 558741 | -0.94 |
| deferred income tax | 1299182 | 18209 | 7034.83 |
| stock based compensation | 52329 | 52329 | 0.00 |
| accounts receivables | 1067494 | -1042910 | 202.36 |
| accounts payables | -623752 | -107274 | -481.46 |
| inventory | -333627 | -900854 | 62.97 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -92445 | -778527 | 88.13 |
| net cash used for investing activites | 17555 | -1663277 | 101.06 |
| debt repayment | -320686 | -174906 | -83.35 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -320686 | -174906 | -83.35 |
| net change in cash | 1153713 | 1306280 | -11.68 |
| cash at end of period | 9999087 | 8845374 | 13.04 |
| cash at beginning of period | 8845374 | 7539094 | 17.33 |
Net Change in Cash: Net Change in Cash decreased to 1 million in 2025Q2 from 1 million in 2025Q1 representing a change of -11.68%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to 1 million in 2025Q2 from 3 million in 2025Q1 representing a change of -53.67%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 1 million in 2025Q2 from 1 million in 2025Q1 representing a change of -6.93%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2025Q2 from -2 million in 2025Q1 representing a change of 94.49%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to 1 million in 2025Q2 from 0 million in 2025Q1 representing a change of 7034.83%. This indicates that the company's tax liability for future periods has increased.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2025Q2 from 0 million in 2025Q1 representing a change of -481.46%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 1 in 2025Q2 from -1 million in 2025Q1 representing a change of 202.36%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q2 2025 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2024-03-31 | 2023-03-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2024 | 2023 | NaN |
| revenue per share | 0.06 | 33.72 | -99.83 |
| net income per share | 0.02 | 4.35 | -99.55 |
| operating cash flow per share | -0.0 | 0.0 | -198.04 |
| free cash flow per share | -0.0 | -0.0 | -70.19 |
| cash per share | 0.01 | 0.01 | -9.50 |
| book value per share | 0.06 | 0.03 | 98.34 |
| tangible book value per share | 0.05 | 0.02 | 125.98 |
| shareholders equity per share | 0.06 | 0.03 | 98.34 |
| interest debt per share | 0.01 | 0.0 | 145.91 |
| market cap | 155362834.54 | 29374429.03 | 428.91 |
| enterprise value | 159994340.54 | 25429470.03 | 529.17 |
| pe ratio | 7.73 | 0.01 | 115890.96 |
| price to sales ratio | 2.74 | 0.0 | 318924.65 |
| pocfratio | -47.34 | 8.8 | -638.12 |
| pfcf ratio | -37.97 | -12.25 | -210.00 |
| pb ratio | 2.7 | 1.01 | 166.00 |
| ptb ratio | 2.7 | 1.01 | 166.00 |
| ev to sales | 2.83 | 0.0 | 379401.81 |
| enterprise value over ebitda | 61.95 | 3.96 | 1466.17 |
| ev to operating cash flow | -48.76 | 7.62 | -740.13 |
| ev to free cash flow | -39.11 | -10.6 | -268.76 |
| earnings yield | 0.13 | 150.13 | -99.91 |
| free cash flow yield | -0.03 | -0.08 | 67.74 |
| debt to equity | 0.2 | 0.13 | 51.86 |
| debt to assets | 0.14 | 0.1 | 47.62 |
| net debt to ebitda | 1.79 | -0.61 | 392.25 |
| current ratio | 3.07 | 2.75 | 11.67 |
| interest coverage | 18.33 | 1819.99 | -98.99 |
| income quality | -0.16 | 0.94 | -117.41 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.12 | 0.15 | -17.98 |
| research and ddevelopement to revenue | 0.12 | 0.18 | -33.04 |
| intangibles to total assets | 0.08 | 0.16 | -51.11 |
| capex to operating cash flow | -0.25 | 1.72 | -114.36 |
| capex to revenue | 0.01 | 0.0 | 8413.14 |
| capex to depreciation | 0.55 | 4.27 | -87.10 |
| stock based compensation to revenue | 0.15 | 0.0 | 886349.90 |
| graham number | 0.16 | 1.67 | -90.50 |
| roic | 6.19 | 67.11 | -90.77 |
| return on tangible assets | 0.26 | 127.62 | -99.80 |
| graham net net | 0.0 | 0.0 | -30.31 |
| working capital | 26964425 | 13676660 | 97.16 |
| tangible asset value | 51241590 | 22619032 | 126.54 |
| net current asset value | 13943471 | 9574539 | 45.63 |
| invested capital | 47915805 | 30457108 | 57.32 |
| average receivables | 11273925 | 3076231 | 266.48 |
| average payables | 2580558 | 1938897.5 | 33.09 |
| average inventory | 11240590 | 8145943 | 37.99 |
| days sales outstanding | 125.39 | 0.03 | 379077.44 |
| days payables outstanding | 32.73 | 0.05 | 64261.48 |
| days of inventory on hand | 155.93 | 0.2 | 78449.90 |
| receivables turnover | 2.91 | 11037.19 | -99.97 |
| payables turnover | 11.15 | 7177.14 | -99.84 |
| inventory turnover | 2.34 | 1838.72 | -99.87 |
| roe | 0.35 | 152.27 | -99.77 |
| capex per share | 0.0 | 0.01 | -85.92 |
ROE: Return on Equity (ROE) decreased to 0.35 on 2024-03-31 from 152.27 on 2023-03-31, representing a change of -99.77%. However, ROE is >= 15%, suggesting that the company has been generating high returns for its shareholders still.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.20 on 2024-03-31 from 0.13 on 2023-03-31, representing a change of 51.86%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 7.73 on 2024-03-31 from 0.01 on 2023-03-31, representing a change of 115890.96%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 3.07 on 2024-03-31 from 2.75 on 2023-03-31, representing a change of 11.67%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
| 2024-09-30 Q2 | 2024-06-30 Q1 | Q/Q change % | |
|---|---|---|---|
| ELTP | |||
| calendar year | 2025 | 2025 | NaN |
| revenue per share | 0.02 | 0.02 | 0.41 |
| net income per share | -0.01 | 0.0 | -1892.26 |
| operating cash flow per share | 0.0 | 0.0 | -53.67 |
| free cash flow per share | 0.0 | 0.0 | -6.93 |
| cash per share | 0.01 | 0.01 | 13.65 |
| book value per share | 0.04 | 0.05 | -18.86 |
| tangible book value per share | 0.04 | 0.05 | -21.53 |
| shareholders equity per share | 0.04 | 0.05 | -18.86 |
| interest debt per share | 0.01 | 0.01 | -2.21 |
| market cap | 414489965.9 | 213547794.29 | 94.10 |
| enterprise value | 416331356.9 | 216804124.29 | 92.03 |
| pe ratio | -9.39 | 86.7 | -110.83 |
| price to sales ratio | 21.95 | 11.36 | 93.30 |
| pocfratio | 284.51 | 67.91 | 318.94 |
| pfcf ratio | 303.79 | 145.67 | 108.54 |
| pb ratio | 8.77 | 3.67 | 139.20 |
| ptb ratio | 8.77 | 3.67 | 139.20 |
| ev to sales | 22.05 | 11.53 | 91.25 |
| enterprise value over ebitda | -47.8 | 130.82 | -136.54 |
| ev to operating cash flow | 285.78 | 68.95 | 314.48 |
| ev to free cash flow | 305.14 | 147.89 | 106.32 |
| earnings yield | -0.03 | 0.0 | -1023.38 |
| free cash flow yield | 0.0 | 0.01 | -52.05 |
| debt to equity | 0.24 | 0.2 | 20.42 |
| debt to assets | 0.13 | 0.13 | -2.68 |
| net debt to ebitda | -0.21 | 1.96 | -110.76 |
| current ratio | 3.52 | 3.08 | 14.42 |
| interest coverage | 13.66 | 15.41 | -11.35 |
| income quality | -0.13 | 5.11 | -102.59 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.12 | 0.1 | 25.14 |
| research and ddevelopement to revenue | 0.1 | 0.12 | -9.50 |
| intangibles to total assets | 0.08 | 0.08 | -0.40 |
| capex to operating cash flow | 0.06 | 0.53 | -88.11 |
| capex to revenue | 0.0 | 0.09 | -94.52 |
| capex to depreciation | 0.17 | 3.0 | -94.44 |
| stock based compensation to revenue | 0.0 | 0.0 | -0.41 |
| graham number | 0.1 | 0.03 | 281.35 |
| roic | 0.05 | 0.04 | 41.27 |
| return on tangible assets | -0.14 | 0.01 | -1884.46 |
| graham net net | -0.01 | 0.0 | -851.55 |
| working capital | 32440129 | 29145905 | 11.30 |
| tangible asset value | 40025792 | 51009692 | -21.53 |
| net current asset value | 4362873 | 13565455 | -67.84 |
| invested capital | 53957408 | 51156222 | 5.48 |
| average receivables | 20964978 | 19969851 | 4.98 |
| average payables | 2295156 | 2660669 | -13.74 |
| average inventory | 13998131.5 | 13380891 | 4.61 |
| days sales outstanding | 102.22 | 98.06 | 4.24 |
| days payables outstanding | 16.71 | 22.72 | -26.45 |
| days of inventory on hand | 119.33 | 120.53 | -0.99 |
| receivables turnover | 0.88 | 0.92 | -4.07 |
| payables turnover | 5.39 | 3.96 | 35.96 |
| inventory turnover | 0.75 | 0.75 | 1.00 |
| roe | -0.23 | 0.01 | -2308.74 |
| capex per share | 0.0 | 0.0 | -94.49 |
ROE: Return on Equity (ROE) decreased to -0.23 on 2024-09-30 Q2 from 0.01 on 2024-06-30 Q1, representing a change of -2308.74%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -9.39 on 2024-09-30 Q2 from 86.70 on 2024-06-30 Q1, representing a change of -110.83%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 3.52 on 2024-09-30 Q2 from 3.08 on 2024-06-30 Q1, representing a change of 14.42%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.24 on 2024-09-30 Q2 from 0.20 on 2024-06-30 Q1, representing a change of 20.42%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 0.05 which is lower than current price 0.48, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2024-12-26 07:00:00
Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Vyvanse® (Lisdexamfetamine Disylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
Sentiment: Negative
Publish Date: 2024-12-02 06:00:00
Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Norco® (hydrocodone bitartrate and acetaminophen tablets, USP CII) 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Hydrocodone and acetaminophen is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Sentiment: Positive
Publish Date: 2024-11-25 15:37:10
Here we highlight a small cap and a microcap with Zacks Outperform ratings.
Sentiment: Positive
Publish Date: 2024-11-18 13:05:23
ELTP sees strong revenue growth despite a net loss, driven by new product launches and strategic acquisitions.
Sentiment: Positive
Publish Date: 2024-11-18 06:00:00
Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Vyvanse® (Lisdexamfetamine Dimesylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Sentiment: Positive
Publish Date: 2024-11-16 15:24:10
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2025 Earnings Conference Call November 15, 2024 11:30 AM ET Company Participants Nasrat Hakim - President and CEO Carter Ward - CFO Conference Call Participants Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Second Quarter of Fiscal Year 2025 Conference Call. At this time all lines have been placed on a listen-only mode.
Sentiment: Positive
Publish Date: 2024-11-14 16:38:00
Conference Call Scheduled for Friday, November 15 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended September 30, 2024, which is the second quarter of the Company's fiscal year ending on March 31, 2025 ("Second Quarter"). Consolidated revenues for the three months ended September 30, 2024, were $18.9 million, an increase of $4.7 million or approximately 33% as compared to the comparable period of the prior fiscal year.
Sentiment: Neutral
Publish Date: 2024-11-07 07:00:00
Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14, 2024 Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2025 fiscal year will be released on Thursday, November 14, 2024. Elite's management will host a live conference call on Friday, November 15th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
